STOCK TITAN

Protalix Biother Stock Price, News & Analysis

PLX NYSE

Welcome to our dedicated page for Protalix Biother news (Ticker: PLX), a resource for investors and traders seeking the latest updates and insights on Protalix Biother stock.

Protalix BioTherapeutics (NYSE: PLX) is a biopharmaceutical innovator leveraging its proprietary ProCellEx® plant cell-based technology to develop enzyme replacement therapies for rare diseases. This page provides investors and industry stakeholders with timely updates on clinical developments, regulatory milestones, and strategic partnerships.

Access comprehensive coverage of PLX's advancements in treating Gaucher disease, Fabry disease, and other rare conditions. Track updates across three key areas: clinical trial progress for pipeline candidates, commercial partnerships with global pharmaceutical leaders, and manufacturing innovations through the ProCellEx® platform.

Our curated news collection enables efficient monitoring of FDA submissions, earnings reports, and licensing agreements. Stay informed about the company's unique approach to cost-effective bioproduction and its expanding role in addressing unmet medical needs through plant-based protein expression systems.

Bookmark this page for direct access to verified press releases and objective analysis of Protalix's position within the competitive rare disease therapeutics market. Regular updates ensure you maintain current awareness of developments impacting both clinical outcomes and investment considerations.

Rhea-AI Summary

Protalix BioTherapeutics (NYSE American:PLX), a biopharmaceutical company specializing in recombinant therapeutic proteins using its proprietary ProCellEx® plant cell-based expression system, has announced its participation in the 2025 BIO CEO & Investor Conference.

The event will take place on February 10-11, 2025, at the New York Marriott Marquis. Company management will deliver a corporate presentation on Tuesday, February 11, 2025, at 10:15 AM EST in the Royale Room. The presentation will subsequently be made available in the Investors section of the company's website under the Event Calendar tab.

Management will also be available for one-on-one meetings with registered investors and conference attendees. Interested parties are encouraged to schedule meetings through the BIO CEO attendee portal.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.13%
Tags
conferences
-
Rhea-AI Summary

Protalix BioTherapeutics (PLX) released its 2025 stockholder letter highlighting key achievements in 2024 and future outlook. The company reports significant progress in its partnership with Chiesi Global Rare Diseases, including EMA's validation of a variation submission for pegunigalsidase alfa to enable less frequent dosing for Fabry disease patients. PLX completed a phase I trial for PRX-115 for uncontrolled gout, with plans to advance to phase II in H2 2025.

The company reports growth in sales across its three revenue streams: Elfabrio® to Chiesi, Elelyso® to Pfizer, and Uplyso® to Brazil. Notably, PLX has achieved debt-free status by fully repaying all outstanding convertible notes. Despite regional conflicts in Israel, operations remain uninterrupted, and the company maintains its focus on R&D in renal rare diseases using its ProCellEx platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.7%
Tags
none
-
Rhea-AI Summary

Chiesi Global Rare Diseases and Protalix BioTherapeutics (PLX) announced the European Medicines Agency's validation of their Variation Submission for pegunigalsidase alfa. The submission aims to approve a less frequent dosing regimen of 2 mg/kg every four weeks for adult Fabry disease patients, compared to the current 1 mg/kg every two weeks.

The application is supported by a revised Population-PK model, exposure-response analyses, and clinical data from the Phase 3 BRIGHT study and its ongoing extension study. The studies investigated the 2 mg/kg every four weeks dosing in adult Fabry disease patients previously treated with agalsidase-alfa or -beta.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.14%
Tags
none
Rhea-AI Summary

Protalix BioTherapeutics (PLX) reported Q3 2024 financial results with revenues from goods of $17.8 million, a 75% increase from Q3 2023. The company achieved net income of $3.2 million ($0.04 per share basic). Key highlights include completion of all eight cohorts in the PRX-115 phase I trial for uncontrolled gout treatment, showing promising preliminary results with sustained uric acid reduction. Cash position stands at $27.4 million as of September 30, 2024. The company fully repaid its 7.50% Senior Secured Convertible Notes and plans to initiate a phase II clinical trial for PRX-115 in the second half of 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.71%
Tags
-
Rhea-AI Summary

Protalix BioTherapeutics (PLX) has scheduled the release of its third quarter 2024 financial results and business update for November 14, 2024. The company will host a conference call and webcast at 8:30 a.m. EST to discuss financial results and provide updates on corporate and regulatory developments. The event will be accessible via toll-free numbers for domestic and international callers, with a Call me™ feature available for immediate connection. A two-week replay will be available on the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.92%
Tags
-
Rhea-AI Summary

Protalix BioTherapeutics (NYSE American:PLX) announced it will present data from its phase I clinical trial of PRX-115, a recombinant PEGylated uricase product candidate for uncontrolled gout treatment, at the ACR Convergence 2024. The presentation, titled 'Prolonged Plasma Urate-Lowering After a Single Intravenous Administration of PRX-115,' will be delivered as a late-breaking poster on November 18, 2024. The study focuses on participants with elevated urate levels, and the results will be presented by Dr. Orit Cohen Barak from Protalix.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.85%
Tags
conferences clinical trial
Rhea-AI Summary

Protalix BioTherapeutics (NYSE American: PLX), a biopharmaceutical company specializing in recombinant therapeutic proteins, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, at the Lotte New York Palace Hotel in New York City.

Company President and CEO Dror Bashan will deliver a presentation on Wednesday, September 11, at 12:30 p.m. EDT in the Holmes II Room on the Fourth floor. The management team will also engage in one-on-one meetings with registered investors throughout the conference.

Protalix is known for its proprietary ProCellEx® plant cell-based protein expression system, which is used in the development and production of recombinant therapeutic proteins.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.61%
Tags
conferences
-
Rhea-AI Summary

Protalix BioTherapeutics (NYSE American: PLX) has announced the full repayment of its 7.50% Senior Secured Convertible Promissory Notes, marking a significant milestone for the company. The repayment was financed entirely with available cash, resulting in Protalix becoming debt-free with no outstanding notes. This move has eliminated the potential equity overhang presented by the notes and strengthened the company's balance sheet.

CEO Dror Bashan highlighted that the company's financial discipline has led to a strong financial position, providing sufficient runway for planned ongoing operations. Protalix, a biopharmaceutical company specializing in recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, had previously relied on convertible notes for financing, with the total outstanding principal amount reaching $78.0 million at its peak.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.32%
Tags
none
-
Rhea-AI Summary

Protalix BioTherapeutics (NYSE American: PLX) reported Q2 2024 financial results and provided a business update. Key highlights include:

- Revenues from selling goods decreased 12% to $13.3 million

- License and R&D services revenue fell 99% to $0.2 million

- Net loss of $2.2 million ($0.03 per share) compared to net income of $19.3 million in Q2 2023

- Cash position of $45 million as of June 30, 2024

- Positive topline results from Phase I trial of PRX-115 for uncontrolled gout

- Preparations initiated for Phase II trial of PRX-115

The company's pipeline progress and strong balance sheet position it to repay convertible notes due September 2024 while maintaining operations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.58%
Tags
Rhea-AI Summary

Protalix BioTherapeutics (NYSE American: PLX) has announced that it will release its financial results for the second quarter of 2024 on August 14, 2024. The company, which specializes in developing recombinant therapeutic proteins using its proprietary ProCellEx® plant cell-based protein expression system, will also provide a business and clinical update during a conference call with investors.

The conference call is scheduled for 8:30 a.m. EDT on August 14, 2024. Investors can join via toll-free numbers for US and Israeli participants, or through an international line. A webcast of the call will also be available, and a replay will be accessible for two weeks on the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags

FAQ

What is the current stock price of Protalix Biother (PLX)?

The current stock price of Protalix Biother (PLX) is $1.55 as of August 28, 2025.

What is the market cap of Protalix Biother (PLX)?

The market cap of Protalix Biother (PLX) is approximately 129.2M.
Protalix Biother

NYSE:PLX

PLX Rankings

PLX Stock Data

129.17M
71.33M
10.54%
15.14%
4.56%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
HACKENSACK